Published in Exp Biol Med (Maywood) on April 24, 2014
The relevance and potential roles of microphysiological systems in biology and medicine. Exp Biol Med (Maywood) (2014) 1.74
Biology coming full circle: joining the whole and the parts. Exp Biol Med (Maywood) (2015) 1.18
A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) (2015) 0.91
Liver and Kidney on Chips: Microphysiological Models to Understand Transporter Function. Clin Pharmacol Ther (2016) 0.87
A novel low-volume two-chamber microfabricated platform for evaluating drug metabolism and toxicity. Technology (Singap World Sci) (2015) 0.85
Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng (2015) 0.83
Nuclear and mitochondrial DNA methylation patterns induced by valproic acid in human hepatocytes. Chem Res Toxicol (2017) 0.83
Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells. Tissue Eng Part C Methods (2014) 0.82
Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. Toxicol Sci (2015) 0.81
Recent advances in bioprinting techniques: approaches, applications and future prospects. J Transl Med (2016) 0.80
Liver metastases: Microenvironments and ex-vivo models. Exp Biol Med (Maywood) (2016) 0.78
Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med (Maywood) (2015) 0.78
Isolation and co-culture of rat parenchymal and non-parenchymal liver cells to evaluate cellular interactions and response. Sci Rep (2016) 0.76
Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays. Biomed Res Int (2017) 0.76
A shift in paradigm towards human biology-based systems for cholestatic-liver diseases. J Physiol (2015) 0.76
Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats. Int J Clin Exp Med (2015) 0.76
Scientific concepts and applications of integrated discrete multiple organ co-culture technology. J Pharmacol Pharmacother (2015) 0.75
Engineering a perfusable 3D human liver platform from iPS cells. Lab Chip (2016) 0.75
Towards engineering integrated cardiac organoids: beating recorded. J Thorac Dis (2016) 0.75
Human Liver Infection in a Dish: Easy-To-Build 3D Liver Models for Studying Microbial Infection. PLoS One (2016) 0.75
Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing? Pharm Res (2016) 0.75
Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions. Tissue Eng Part B Rev (2016) 0.75
Exposure to the environmental endocrine disruptor TCDD and human reproductive dysfunction: Translating lessons from murine models. Reprod Toxicol (2016) 0.75
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol (2004) 36.25
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature (1997) 18.83
Understanding, improving and using green fluorescent proteins. Trends Biochem Sci (1995) 7.51
Circularly permuted green fluorescent proteins engineered to sense Ca2+. Proc Natl Acad Sci U S A (2001) 6.63
Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol (2004) 6.36
New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc (2002) 5.83
Microscale culture of human liver cells for drug development. Nat Biotechnol (2007) 4.85
Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators. J Biol Chem (2004) 4.75
Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000) 4.58
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc Natl Acad Sci U S A (2001) 3.77
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov (2005) 3.23
Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog (1991) 3.21
Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J (1989) 2.89
Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl Acad Sci U S A (2001) 2.77
Fluorogen-activating single-chain antibodies for imaging cell surface proteins. Nat Biotechnol (2007) 2.45
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol (2006) 2.12
Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos (2003) 2.01
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol (2003) 1.97
Genetically encoded biosensors based on engineered fluorescent proteins. Chem Soc Rev (2009) 1.95
Perfused multiwell plate for 3D liver tissue engineering. Lab Chip (2009) 1.88
A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng (2002) 1.87
ACToR--Aggregated Computational Toxicology Resource. Toxicol Appl Pharmacol (2008) 1.75
An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng (2007) 1.75
First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov (2004) 1.73
BDDCS applied to over 900 drugs. AAPS J (2011) 1.68
Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65
A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab (2005) 1.61
Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci (2001) 1.59
Why drugs fail--a study on side effects in new chemical entities. Curr Pharm Des (2005) 1.54
Microfabrication and microfluidics for tissue engineering: state of the art and future opportunities. Lab Chip (2004) 1.53
Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J Cell Biol (1992) 1.53
Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology (2004) 1.51
Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci (2008) 1.49
Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol (2013) 1.49
Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol (2012) 1.46
Liver cell models in in vitro toxicology. Environ Health Perspect (1998) 1.42
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Novel fluorescent indicator proteins for monitoring free intracellular Ca2+. Cell Calcium (1997) 1.39
Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol (2005) 1.38
Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol (2012) 1.36
Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. Hepatology (2009) 1.33
Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos (1999) 1.32
T3DB: a comprehensively annotated database of common toxins and their targets. Nucleic Acids Res (2009) 1.32
Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. Proc Natl Acad Sci U S A (2009) 1.32
Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol (2007) 1.27
A fluorescent protein biosensor of myosin II regulatory light chain phosphorylation reports a gradient of phosphorylated myosin II in migrating cells. Mol Biol Cell (1995) 1.26
A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol (2013) 1.25
Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther (2006) 1.21
Split-protein systems: beyond binary protein-protein interactions. Curr Opin Chem Biol (2011) 1.21
Phenotypic anchoring: linking cause and effect. Environ Health Perspect (2003) 1.21
Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett (2008) 1.20
Mechanochemical manipulation of hepatocyte aggregation can selectively induce or repress liver-specific function. Biotechnol Bioeng (2000) 1.18
Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng (2002) 1.16
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos (2009) 1.15
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci (2011) 1.14
Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther (2009) 1.14
Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J (2009) 1.12
Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther (1999) 1.12
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci (2013) 1.11
Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci (2005) 1.09
Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol (2005) 1.08
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol (2010) 1.08
Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos (2004) 1.08
Paradigm shift in toxicity testing and modeling. AAPS J (2012) 1.07
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol (2011) 1.06
A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip (2010) 1.06
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci (2011) 1.04
New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev (2003) 1.04
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci (2011) 1.03
Computational toxicology--a tool for early safety evaluation. Drug Discov Today (2009) 1.01
Polyelectrolyte nano-scaffolds for the design of layered cellular architectures. Tissue Eng (2006) 1.00
A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol (2009) 0.99
Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol (2009) 0.98
Fluorescent biosensors of intracellular targets from genetically encoded reporters to modular polypeptide probes. Cell Biochem Biophys (2010) 0.97
Modulation of hepatocyte phenotype in vitro via chemomechanical tuning of polyelectrolyte multilayers. Biomaterials (2008) 0.97
Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity. PLoS One (2013) 0.96
Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol (2013) 0.94
Microfluidic environment for high density hepatocyte culture. Biomed Microdevices (2008) 0.93
The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos (2014) 0.93
Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies. Biotechnol Bioeng (2010) 0.93
Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci (2012) 0.90
Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos (2007) 0.89
Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen (2010) 0.88
Land-based versus pool-based exercise for people awaiting joint replacement surgery of the hip or knee: results of a randomized controlled trial. Arch Phys Med Rehabil (2009) 0.88
Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J Gastroenterol (2013) 0.88
Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos (2013) 0.88
Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos (2010) 0.87
EU framework 6 project: predictive toxicology (PredTox)--overview and outcome. Toxicol Appl Pharmacol (2010) 0.87
The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol (2014) 0.87
Organ slice viability extended for pathway characterization: an in vitro model to investigate fibrosis. Toxicol Sci (2004) 0.86
Redesign of genetically encoded biosensors for monitoring mitochondrial redox status in a broad range of model eukaryotes. J Biomol Screen (2013) 0.86
Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell (2012) 0.85
Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica (2006) 0.83
Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. J Hepatol (2006) 0.82
Repair pathways evident in human liver organ slices. Toxicol In Vitro (2011) 0.82